NR4A2-driven metabolic reprogramming in the heart: from adaptive response to maladaptive remodeling.
Stujanna EN, Yoshioka J
This study examines how the NR4A2 protein influences heart metabolism and remodeling, focusing on cardiac tissue rather than the brain. It does not provide information relevant to neurodevelopmental symptoms or treatment options for children with NR4A2-related syndromes.
- Research focuses on heart tissue and metabolic reprogramming mechanisms.
- Findings relate to cardiac remodeling, not neurological development.
- No data on human patients with NR4A2 variants is included.
- Results do not inform current clinical management or therapies.
Downregulated transcription in chromosomal domains of midbrain dopamine neurons linked to schizophrenia.
Singh S, Iskhakova M, Lambert TY, Valada A, Shokrian N, Evans V, Bendl J, Auluck PK, Marenco S, Wang M, Zhang B, Hoffman GE, Girdhar K, Roussos P, Akbarian S
This study identifies specific genes that are turned down in the dopamine neurons of people with schizophrenia, linking these changes to organized regions of DNA called chromosomal domains. It highlights several known risk genes for neurological conditions within these affected areas.
- Researchers analyzed dopamine neuron DNA from schizophrenia donors compared to controls.
- 331 genes were found to be downregulated in these specific brain cells.
- Affected genes include FOXP1, MAPK10, PCM1, and NRXN1.
- Changes cluster within topologically associated chromosomal domains unique to dopamine neurons.
- The study focuses on schizophrenia pathophysiology rather than NR4A2-related syndromes.
Cytokine armored CAR T cells for cancer immunotherapy.
Sek K, Yap KM, Hong WX, Darcy PK
This study explores using the NR4A2 gene promoter to control the release of immune-stimulating proteins in cancer immunotherapy, aiming to reduce side effects. It does not investigate NR4A2's role in human neurodevelopment or treat conditions relevant to your child.
- NR4A2 promoter restricts cytokine expression to improve safety in cancer therapy.
- Focus is on engineering CAR T cells for tumor treatment.
- No clinical data or relevance to NR4A2-related neurodevelopmental disorders.
Aberrant immune regulation and enrichment of stem-like CD8+ T cells in the pancreatic lymph node during type 1 diabetes development.
Peters LD, Seay HR, Smith J, Posgai AL, Berkowitz R, Wasserfall CH, Atkinson MA, Bacher R, Brusko MA, Brusko TM
This study maps immune cell changes in the pancreas of people with type 1 diabetes to understand how T cells attack insulin-producing cells. It identifies specific T cell populations and signaling pathways that drive this autoimmune process. The findings offer potential targets for immunotherapies aimed at stopping or reversing type 1 diabetes.
- Researchers analyzed pancreatic lymph nodes from humans with type 1 diabetes using advanced sequencing.
- A specific group of stem-like CD8+ T cells accumulates in the affected tissue.
- These cells show reduced expression of exhaustion markers, including NR4A2.
- IL-15 signaling drives the expansion and behavior of these pathogenic T cells.
- T cells in the pancreas are closer to insulin-producing islets than those in lymph nodes.
miR-19a-3p and miR-19b-3p repress Nurr1 and Nur77 to promote microglial inflammation after spinal cord injury.
Sahebdel F, Zia A, Quintá HR, Stucky A, Morse LR, Olson JK, Battaglino RA
This study shows that specific microRNAs increase inflammation in spinal cord injury models by suppressing the NR4A2-related proteins Nurr1 and Nur77. The research uses rat models and cell cultures to demonstrate this mechanism, which is unrelated to the developmental or dopaminergic contexts of NR4A2 syndrome.
- The study focuses on spinal cord injury pain, not NR4A2 syndrome development.
- It uses rat models and microglia cells, providing no human clinical data.
- NR4A2 appears only as a general inflammatory regulator in this context.
- There is no stated path to treatment for NR4A2-related conditions.
Janus kinase 2 regulates Nurr1 protein stability in dopaminergic neurons of the aging midbrain.
Jang Y, Kim YH, Jeon J, Cha Y, Lopes C, Jung JH, Oh E, Park Y, Ko C, Hyeon B, Leblanc P, Kim KS
This study identifies JAK2 as a protein that stabilizes Nurr1 (NR4A2) in dopaminergic neurons, protecting them from oxidative stress. The findings are based on mouse models and cell lines, showing that JAK2 maintains Nurr1 levels independently of standard signaling pathways.
- JAK2 physically interacts with Nurr1 to stabilize the protein in aging midbrain neurons.
- This stabilization reduces oxidative stress and protects dopaminergic cells from damage.
- The mechanism operates independently of canonical JAK/STAT or PI3K/Akt signaling pathways.
- Results come exclusively from aged mice and neuroblastoma cell cultures.
Nuclear receptor subfamily 4 group a member 2 induces a Warburg-like effect and promotes phospholipids synthesis in the mouse heart.
Ashraf S, Odogwu D, McPherson DD, Harmancey R
NR4A2 activation in mouse heart cells reprograms metabolism to favor glycolysis and phospholipid production, which initially may be adaptive but leads to declining heart function over time.
- NR4A2 turns on genes for glucose use and fat breakdown suppression
- Heart cells shift to making building blocks instead of energy
- Long-term NR4A2 activation harms heart pumping ability
- This metabolic switch may explain heart failure in stress conditions
MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation.
Cheng C, Su H, Li X, Li R, Yang Q, Guan T, Li M, Ou C
miR-1290 in natural killer cell vesicles drives immune imbalance in lupus nephritis by suppressing NR4A2, a key regulator of immune cell balance. Blocking miR-1290 with engineered vesicles restored immune balance and reduced kidney damage in lupus mice.
- miR-1290 in NK cell vesicles disrupts immune balance in lupus
- miR-1290 suppresses NR4A2, promoting harmful immune cells
- Blocking miR-1290 restored immune balance in lupus mice
- Engineered vesicles delivered therapy effectively
- NR4A2 is a critical target in immune regulation
A series of extraskeletal myxoid chondrosarcomas with rare morphological and molecular variations.
Chen X, He X, Peng R, Chen M, Zhang H
This study describes five rare cases of extraskeletal myxoid chondrosarcoma with unusual tumor features and new genetic fusions, including a novel FUS::NR4A2 fusion. The tumors showed diverse growth patterns and no recurrence or spread during follow-up. These findings expand the known range of this cancer's appearance and genetics.
- NR4A2 fusion found in a soft tissue sarcoma
- Tumors had unusual shapes and growth patterns
- No recurrence or spread after treatment
- New genetic changes identified in cancer
- Findings may help diagnose rare sarcomas
Differential Responsiveness of Human Skin Mast Cells to SCF and IL-33: Reduced Reactivity to SCF but Not to IL-33 in the Post-Mitotic Phase.
Jin M, Schneikert J, Wegner A, Zuberbier T, Babina M
Human skin mast cells become more sensitive to IL-33 and less responsive to SCF as they age and stop dividing, but their ability to release key inflammatory cytokines remains intact. This shift may help explain why chronic skin conditions persist even as mast cells age.
- Aged mast cells respond less to SCF but more to IL-33
- Cytokine release remains strong despite reduced SCF sensitivity
- IL-33 becomes a more potent trigger in non-dividing mast cells
- SCF signaling weakens over time, but not completely lost
- This shift may support ongoing inflammation in chronic skin disease
Momordicine I, a triterpene from bitter melon (Momordica charantia L.), ameliorates alcohol-associated liver disease: research on the possible liver benefits.
Hou Y, Wang SY, Xu ZY, Xin G, Zhao GY, Sun HM
This study shows that Momordicine I, a compound from bitter melon, protects liver cells in mice by activating the Nurr1 protein to reduce inflammation and fat buildup. The research confirms that Nurr1 is necessary for this protective effect, as silencing it removes the benefits of the treatment.
- Momordicine I activates Nurr1 to lower lipid synthesis and inflammation in liver cells.
- The compound improves mitochondrial function and reduces inflammatory markers in mice.
- Silencing Nurr1 eliminates the protective effects, proving its central role.
- Nurr1-deficient mice suffer worse liver damage, highlighting the protein's importance.
Mechanistic insights into the role of nuclear receptor related-1 protein in Parkinson's disease.
Sharma V, Singh TG
This review explains how the Nurr1 protein supports dopamine neuron survival and reduces brain inflammation, while its loss contributes to Parkinson's disease pathology. It outlines molecular pathways that regulate Nurr1 and identifies potential strategies for therapies that could restore its function.
- Nurr1 maintains dopamine neuron health and regulates genes for dopamine production.
- The protein suppresses neuroinflammation by blocking pro-inflammatory signals in glial cells.
- Loss of Nurr1 impairs mitochondrial function and increases vulnerability to oxidative stress.
- Current research targets manipulating Nurr1 function as a potential Parkinson's therapy.
De novo identification of potent ingredients for proteasome activation in MT101-5 using an AI-driven approach.
Kim S, Han M, Kim SW, Choi JG, Park SC, Choi SI, Son M, Lee D
Two specific plant-derived compounds in the herbal formula MT101-5 restore proteasome function and reduce alpha-synuclein buildup in mouse models of Parkinson's disease. These compounds also improve motor behavior and protect dopamine neurons in these animals, suggesting a potential mechanism for treating neurodegenerative conditions involving protein aggregation.
- Compounds from Genkwae Flos activate the proteasome via Nurr1 to clear alpha-synuclein aggregates.
- Two diterpenoids reduced motor deficits and dopamine neuron loss in MPTP-treated mice.
- The study uses an AI-driven network analysis to identify active ingredients in MT101-5.
- Findings provide preliminary evidence for MT101-5 as a potential treatment for Parkinson's disease.
Forward Programming Identifies Inducers of Blood-Brain Barrier Properties in Human Pluripotent Stem Cell-Derived Endothelial Cells.
Tamhankar S, Ding Y, Hashjin FY, Boutom SM, Daneman R, Palecek SP, Shusta EV
Researchers identify specific transcription factors, including NR4A2, that can program human stem cells to develop blood-brain barrier properties. This work provides tools for modeling neurovascular diseases and screening drugs but does not address motor symptoms or treatment for NR4A2-related syndromes.
- NR4A2 helps induce blood-brain barrier gene expression in stem cell-derived endothelial cells.
- The study focuses on vascular biology, not dopaminergic neurons or motor function.
- Results offer models for drug screening but no direct clinical application for NR4A2 syndrome.
- This is preclinical research with no human patient data or therapeutic testing.
Structure-activity landscape of Nurr1 (NR4A2) modulators: medicinal chemistry strategies for neurodegenerative disease intervention.
Jaidka S, Kumar A, Singh TG, Bhatia R, Singh RK
This review analyzes the chemical structures and effectiveness of various drugs designed to target the Nurr1 protein, which is critical for dopamine neuron health. It highlights that while some compounds show promise in binding to Nurr1, significant challenges remain in ensuring they are selective enough and can effectively reach the brain.
- Nurr1 regulates key genes for dopamine neuron survival and function.
- Current drug candidates lack sufficient selectivity among related nuclear receptors.
- Achieving blood-brain barrier penetration remains a major hurdle.
- In vivo efficacy data is currently inconsistent or lacking.
Functional roles of NR4A transcription factors in GnRH regulation of gonadotropin gene expression and secretion in rat primary pituitary cells.
Terashima R, Tomiyama Y, Kurusu S, Kawaminami M
NR4A transcription factors help control the production and release of FSH and LH hormones in response to GnRH signals in pituitary cells. Knocking down NR4A genes reduces FSH and LH secretion, showing they are key players in hormone regulation.
- NR4A factors are activated by GnRH within an hour
- NR4A2 helps drive FSH production and release
- NR4A knockdown reduces both FSH and LH secretion
- NR4A1 has the strongest effect on FSH levels
- NR4A factors act downstream of GnRH signaling
Renalase stimulates aldosterone production via PMCA4b/cAMP in NCI-H295R cells.
Fu R, Huang M, Liu T, Chen Y, Li X, Jiang W
Renalase stimulates aldosterone production in adrenal cells by binding to the PMCA4b receptor and activating a signaling pathway that increases NR4A2 levels. This mechanism links renalase to hormonal regulation in the adrenal gland rather than providing insight into NR4A2's role in neurodevelopment or potential treatments for NR4A2-related syndromes.
- Renalase increases aldosterone production without affecting cell growth.
- The effect relies on binding to the PMCA4b receptor on the cell surface.
- Signaling involves cAMP/PKA pathways and upregulation of NR4A2 transcription factor.
- Study focuses on adrenal hormone regulation, not brain development or function.
Single-Cell Transcriptomics and Integrated Bioinformatic Analysis Reveal Critical Biomarkers and Immune Infiltration Characteristics in Osteoarthritis.
Gao T, Yang C, Bi Y, Zou P, Wan M, Lan S, Song Y, Xu Y
This study identifies NR4A2 as a key gene associated with osteoarthritis and suggests the drug bexarotene may bind to it. The research focuses on joint inflammation and cartilage degradation rather than neurological development or function. It provides no evidence regarding the safety, efficacy, or relevance of any treatments for NR4A2-related syndromes in children.
- NR4A2 appears as a biomarker in osteoarthritis, not neurodevelopmental research.
- Bexarotene shows binding affinity to NR4A2 in computer simulations only.
- No human clinical data or neurological outcomes are reported.
- Findings relate to joint disease mechanisms, not dopaminergic pathways.
The orphan nuclear receptor NR4A3 is dispensable for resident memory CD8+ T-cell generation.
Odagiu L, Boulet S, De Sousa DM, Daudelin JF, Labrecque N
NR4A3 does not play a role in the development or maintenance of resident memory CD8+ T-cells, unlike its relatives NR4A1 and NR4A2, which are important for this process.
- NR4A3 is not needed for CD8+ Trm cell formation
- NR4A1 and NR4A2 are important for Trm cells, but not NR4A3
- NR4A3 does not affect Trm cells in epithelial or non-epithelial tissues
- NR4A3 expression in Trm cells is not functionally significant
A Commentary on Dual Orphan Nuclear Receptor 4A1 (NR4A1) and NR4A2 Ligands.
Safe S, Cai JJ, Chapkin RS
DIM-3,5 compounds bind and block NR4A1 and NR4A2, reducing cancer and endometriosis cell growth by stopping pro-disease pathways and triggering cell death, and they also affect immune cells in tumors.
- DIM-3,5 compounds inhibit both NR4A1 and NR4A2 receptors.
- These compounds stop cancer and endometriosis cell growth and survival.
- They trigger ferroptosis, a form of cell death, in cancer cells.
- The compounds work in tumor-infiltrating immune cells that express NR4A1/2.
Exploring the Mechanism of Shexiang Baoxin Pill in the Treatment of Ischemic Stroke: A Study Integrating Network Pharmacology, Machine Learning, Molecular Docking, and Molecular Dynamics Simulation.
Fu J, Wang Y, Li X, Dong X
This computational study identifies NR4A2 as one of six potential targets through which Shexiang Baoxin Pill might influence ischemic stroke pathways. The research relies entirely on bioinformatics and molecular simulations to predict how herbal compounds interact with inflammatory genes, including NR4A2, JUN, and TNF. It provides no experimental data on human patients or direct therapeutic effects for NR4A2-related syndromes.
- NR4A2 appears as one of six candidate targets identified via network pharmacology analysis.
- The study uses only computational methods like molecular docking and machine learning simulations.
- No experimental validation or clinical data regarding NR4A2 function or treatment is included.
- Research focuses on ischemic stroke mechanisms rather than NR4A2-related developmental syndromes.
CD4+ Effector Memory T Cells Related Marker Gene Signatures in Osteoporosis and Aging: Insight From Single-Cell Analysis and Mendelian Randomization.
Shi X, Tang L, Li M, Wu Y, Xu Y
This study links aging and osteoporosis through immune cells, finding that CD4+ effector memory T cells increase in both conditions. It identifies NR4A2 as a key gene downregulated in osteoporosis, suggesting its role in immune cell communication and disease development.
- CD4+ effector memory T cells increase in osteoporosis and aging
- NR4A2 is downregulated in osteoporosis patients
- NR4A2 may affect immune cell communication
- KLRB1 and S100A4 are upregulated and linked to osteoporosis
- Findings suggest immune pathways as potential treatment targets
Nurr1 Orchestrates Claustrum Development and Functionality.
Yan K, Newman AG, Lange P, Müller S, Foddis M, Koch SP, Böhm-Sturm P, Mantwill M, Finke C, Deng P, Long M, Schmitz D, Tarabykin V
Nurr1 directs the development and connectivity of the claustrum, a brain region involved in coordinating cognitive behaviors. Without Nurr1, cells migrate incorrectly and form abnormal connections, leading to dysregulated behavior in mice. This study identifies a specific signaling pathway that Nurr1 suppresses to ensure proper brain structure.
- Nurr1 is essential for claustrum formation and connectivity in the developing brain.
- Lack of Nurr1 causes cells to migrate into the wrong brain area.
- Abnormal cell placement disrupts functional connections and behavioral control.
- Nurr1 works by suppressing Gαs-PKA signaling during development.
Prolonged Loss of Oxidative Phosphorylation and Mitochondrial Mass Characterize CD66b+ Leukocytes from Patients with Sepsis.
Rodhouse C, Barrios EL, Zeumer-Spataro L, Balzano-Nogueira L, Wu R, Yu X, Tian G, Brant JO, Gauthier ML, Chen J, Hernandez-Rios M, Polcz VE, Wiggins W, Charles AM, Dirain ML, Ungaro R, Rincon J, Loftus T, Xiao F, Cai G, Moldawer LL, Maile R, Kladde MP, Efron PA, Mathews CE
This study finds that NR4A2 expression is persistently decreased in immune cells from sepsis patients, linking this gene silencing to long-term mitochondrial dysfunction. The research focuses on the role of NR4A2 in regulating metabolism within white blood cells during and after severe infection. It does not provide evidence regarding neurodevelopmental outcomes or treatment strategies for children with NR4A2-related syndromes.
- NR4A2 expression is silenced in immune cells from sepsis patients for up to six months.
- This gene silencing correlates with reduced mitochondrial mass and oxidative metabolism.
- The study examines white blood cell function, not brain development or neurology.
- Findings relate to sepsis recovery mechanisms rather than NR4A2 syndrome phenotypes.
The multiple mechanisms of NR4A2 in neurological disorders and advances in targeted therapy research.
Duan K, Yang C, Gao D, Li M, Chen M, Li H, Zeng W, Zhao L, Zhu M
This review summarizes how NR4A2 influences various neurological conditions, including Parkinson's disease and neurodevelopmental disorders. It outlines potential therapeutic strategies such as agonists and gene therapy but does not present new clinical data or human trial results.
- NR4A2 regulates dopaminergic neurons, synaptic plasticity, and neuroinflammation across multiple brain disorders.
- The paper reviews NR4A2's role in Parkinson's, Alzheimer's, MS, psychiatric issues, and stroke.
- It highlights emerging therapies like NR4A2 agonists and gene-based cell replacement strategies.
- No human clinical trial data or specific genotype-phenotype correlations for NR4A2 variants are included.
Essential function of Nr4a2 in subicular development and social novelty.
Liu XY, Tao YC, Zhang Q, Liu WT, Zhao L, Hu ZB, Zhou BY, Li ZX, Qi CC, Zhang L, Chen JY, Song NN, Ding YQ
This study shows that Nr4a2 is required for the proper development and connectivity of specific brain regions involved in social behavior, as its loss causes social deficits in mice. The findings suggest that Nr4a2 dysfunction may contribute to neurodevelopmental disorders by disrupting hippocampal circuitry.
- Nr4a2 establishes the molecular identity and connectivity of subicular neurons.
- Loss of Nr4a2 causes deficits in social novelty behavior in mice.
- Nr4a2 directly binds to and promotes transcription of subicular genes.
- Dysfunction may contribute to hippocampus-related neurodevelopmental disorders.
Monogenic defects in Russian children with autism spectrum disorders.
Suspitsin EN, Malysheva KS, Laptiev SA, Sharonova OS, Abuzova AS, Kuznitsyna AA, Melashenko TV, Efremova OV, Korzun PR, Binnatova JO, Gorgul YA, Syomina MV, Imyanitov EN
This study identifies NR4A2 as one of many genes with rare variants in children with autism, but it does not provide specific clinical data for NR4A2-related syndrome. The findings confirm that genetic causes of autism are highly diverse and that single mutations in NR4A2 are rare within this cohort.
- NR4A2 appears in a list of genes with rare variants of unknown significance in autistic children.
- No specific NR4A2 variant was found more than once in unrelated patients.
- The study focuses on broad genetic screening rather than detailed NR4A2 phenotypes.
- Results highlight the heterogeneity of genetic causes for autism spectrum disorders.
Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis.
Ye Q, Lai X, Liu Y, Zhang Z, Fu Y, Luo J, Liu C, Duan J, Ding H, Liu Y, Ao Z, Tao Y, Ai S, Huang W, Jiang L, Liu Y, Xu F, Cao J
This study analyzes immune responses in sepsis patients and identifies a specific T cell subset marked by NR4A2 that is associated with disease severity. Genetic experiments in models show that reducing NR4A2 levels improves survival, while increasing them worsens outcomes. The findings highlight anatomical-specific immune patterns but do not provide direct evidence for treating NR4A2-related syndromes.
- NR4A2 marks exhausted central memory CD4+ T cells in sepsis patients.
- Reducing Nr4a2 improves survival in genetic model studies.
- Increasing Nr4a2 worsens survival in genetic model studies.
- The research focuses on infection immunity, not NR4A2 syndrome pathophysiology.
- No clinical data or treatments for NR4A2-related conditions are presented.
NR4A nuclear receptor expression in human macrophages mediates apoptosis and controls Mycobacterium tuberculosis growth.
Simper JD, Jarvis N, Pahari S, Ortega D, Azad A, Safe S, Arnett E, Schlesinger LS
NR4A nuclear receptors are highly active in human lung macrophages and help control tuberculosis by triggering cell death (apoptosis) in infected cells. Blocking these receptors increases tuberculosis growth, while activating them reduces it, suggesting they could be targeted for new treatments.
- NR4A receptors are highly expressed in lung macrophages
- They promote apoptosis to limit tuberculosis growth
- Activating NR4A reduces TB growth in human cells
- NR4A blockers increase TB survival in macrophages
- NR4A receptors are potential targets for new TB therapies
Midnight darkness and evening melatonin pre-treatment reverse night-light-induced neurobehavioural disruptions in a diurnal corvid.
Buniyaadi A, Prabhat A, Bhardwaj SK, Kumar V
Evening melatonin pre-treatment completely reverses the negative effects of dim light at night on sleep, mood, and cognitive performance in crows. This intervention also restores normal gene expression levels for brain health markers, including NR4A2, which are disrupted by artificial light exposure.
- Dim light at night disrupts sleep, mood, and cognition in diurnal birds.
- Nightlight exposure lowers melatonin and alters NR4A2 gene expression in the brain.
- Evening melatonin pre-treatment fully restores normal behavior and gene profiles.
- Midnight darkness offers only partial restoration of these disrupted functions.
Similarities of neocortical deep layer Oprk1-positive neurons and claustrum neurons in connectivity and activity.
Fang C, Zhou H, Brecht M, Wang H, Naumann RK
This study identifies a specific group of deep-layer neocortical neurons that share molecular markers and connectivity patterns with claustrum cells, suggesting they form a parallel circuit involved in brain state synchronization. While the research confirms these neurons express Nurr1 (NR4A2), it focuses entirely on their anatomical connections and activity in rats without addressing NR4A2-related syndromes or potential treatments.
- Deep-layer cortical neurons share markers like Oprk1 and Nurr1 with claustrum cells.
- Both cell types connect primarily to the cortex but target different regions.
- Rat study shows synchronized activity in both groups during anesthesia or novelty.
- No human data, clinical relevance, or treatment implications are presented.
The Nuclear Receptor Nurr1 Modulates the Expression and Activity of PPARγ in Human Pro-Inflammatory Macrophages.
Santana-Cisneros E, Solís-Barbosa MA, Segovia-Gamboa NC, Meraz-Ríos MA, González-Domínguez E, Hernández-Rivas R, Marrero-Rodríguez D, Sanchez-Torres C
This study shows that Nurr1 enhances the activity of PPARγ in human immune cells by stabilizing the protein and reducing inhibitory signals. It does not provide evidence for treating NR4A2-related syndromes or addressing dopaminergic neuron loss.
- Nurr1 increases PPARγ levels by stabilizing the protein in human macrophages.
- Nurr1 activation reduces repressive phosphorylation on PPARγ, boosting its activity.
- Both Nurr1 and PPARγ agonists show anti-inflammatory effects independently.
- The study focuses on immune cell regulation, not neurological function.